ABSTRACT
The main goal of treating group 2 pulmonary hypertension (PH) is targeting the determinants of an abnormal increase in left atrial pressure, whether it is triggered by abnormalities in left ventricular relaxation and filling or valve disease, because no pharmacological therapy is approved. Guidelines (1) and consensus statements (2) advise that comorbid disorders be treated, volume status be optimized, and left ventricular (LV) relaxation properties be improved as mainstay interventions unless correction of valve disease (primarily mitral insufficiency), LV assist devices (LVADs), and heart transplantation (HTX) are indicated.
